NitroMed Publishes BiDil Cost-Effectiveness Study as Therapy Moves Toward PGx Status | GenomeWeb

BiDil — the only drug indicated for use in patients of a specific, self-reported race — can lower the cost of treatment for heart failure, according to a cost-effectiveness study published this week.

The study, printed in the current issue of the American Heart Association journal Circulation, helps promote the uniquely indicated drug, and may add to the relatively small amount of information currently available on the cost effectiveness of pharmacogenomic therapies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.